DDrare: Database of Drug Development for Rare Diseases

74. 下垂体性PRL分泌亢進症
［臨床試験数：18，薬物数：33（DrugBank：10），標的遺伝子数：16，標的パスウェイ数：63］

Searched query = "Prolactin secreting pituitary adenoma", "Pituitary PRL secretion hyperthyroidism", "Prolactinoma", "Prolactin secreting adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Bromocriptine; Cabergoline; Clomiphene; Clomiphene citrate; Curcumin; Dexamethasone; Dopamine; Dopamine Agonists; Dopamine agonist treatment; Drug treatment; Gamma-secretase/Notch signalling pathway inhibitor RO4929097; Genotropin 12mg; Genotropin 5.3mg; Genotropin Miniqu; Genotropin Miniquick 0.2mg; Genotropin Miniquick 0.4mg; Genotropin Miniquick 0.6mg; Genotropin Miniquick 0.8mg; Genotropin Miniquick 1.0mg; Genotropin Miniquick 1.2mg; HCQ/CQ and CAB combined treatment; Lapatinib; Other: Surgery; Other: diagnostic laboratory biomarker analysis; Other: pharmacological study; PASIREOTIDE; Pasireotide; Procedure: Endoscopic trans-sphenoidal adenoma resection; Procedure: transsphenoidal surgery treatment; Ropinirole; SOM230; SOMATROPIN; Somatropin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00939523 (ClinicalTrials.gov)	July 2009	14/7/2009	Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy	Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy	Pituitary Adenomas;Prolactinomas	Drug: Lapatinib	Cedars-Sinai Medical Center	NULL	Completed	18 Years	N/A	All	9	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00939523
(ClinicalTrials.gov)

July 2009

14/7/2009

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Pituitary Adenomas;Prolactinomas

Drug: Lapatinib

Cedars-Sinai Medical Center

NULL

Completed

18 Years

N/A

All

Phase 2

United States